Composite
67%
Novelty
68%
Feasibility
72%
Impact
73%
Mechanistic
81%
Druggability
62%
Safety
52%
Confidence
71%

Mechanistic description

This hypothesis reconciles conflicting C1q phenotypes by placing receiver-cell state downstream of a common upstream C1q-tagging event. In a competent TREM2 program, microglia clear tagged material efficiently; in TREM2-impaired states, the same substrates persist, amplifying complement and bystander synapse loss.

Evidence for (7)

  • TREM2 directly interacts with C1q in neurodegeneration-relevant contexts and appears to restrain complement-mediated synapse loss.

  • Microglial state is a major determinant of neurodegenerative response programs, making it plausible that identical opsonized substrates can lead to different outcomes.

  • TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.

    PMID:36306735 2022 Cell
  • TREM2, microglia, and Alzheimer's disease.

    PMID:33516818 2021 Mech Ageing Dev
  • Microglia and TREM2.

    PMID:38821351 2024 Neuropharmacology
  • A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.

    PMID:28602351 2017 Cell
  • Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model.

    PMID:32579671 2020 J Exp Med

Evidence against (2)

  • TREM2 biology is pleiotropic, and observed effects may reflect broader changes in metabolism, clustering, or plaque handling rather than a specific C1q decision node.

  • The claim that TREM2 state alone determines adaptive versus toxic handling likely overstates causality because astrocytes, other receptors, and complement regulators also shape outcome.

Bayesian persona consensus

62% posterior support

2 signals · 2 for / 0 against · agreement 100%

scidex.consensus.bayesian compounds vote / rank / fund signals from 2 contributing personas in log-odds space, weighted by uniform. Prior 50%.